The main objective of our work was to describe the clinical and demographic characteristics of patients with MND treated with riluzole by comparing those taking it in oral suspension to those taking tablets. In addition, we looked at the impact on survival in patients in our cohort with and without dysphagia according to how (oral suspension vs tablets) the riluzole treatment was being administered.
We concluded that the most appropriate dosage form should be given according to the patient's needs at each stage of the disease and, furthermore, oral suspension could improve adherence to treatment because it avoids having to change from one form (tablet) to the other (suspension) when swallowing disorders appear.